Marcén R, Pascual J, Tato A, Villafruela J J, Teruel J L, Rivera M E, Tenorio M, Fernández M, Burgos F J, Ortuño J
Department of Nephrology, Hospital Ramón y Cajal, Universidad de Alcalá de Henares, Madrid, Spain.
Transplant Proc. 2003 Aug;35(5):1780-2. doi: 10.1016/s0041-1345(03)00579-7.
Recent data show that monitoring cyclosporine A (CsA) concentrations with 2-hour postdose levels (C2) correlates with the incidence of rejection and graft outcome in de novo renal transplant patients. The purpose of the present work was to evaluate the advantage of C2 monitoring after the first year of kidney transplantation. We studied 161 patients, 96 on CsA-prednisone and 65 on triple therapy (Aza or MMF) who had been transplanted for a mean of 103+/-44 months. Mean serum creatinine (SCr) was 1.65+/-0.69 mg/dL, mean C0 was 174+/-44, and C2 was 667+/-194 ng/mL. Patients were classified according to C2 values: >850 (n=29), between 850 and 450 (n=109), and <450 (n=23) ng/mL. Patients with C2 <450 ng/mL displayed higher SCr values (1.97+/-0.99; 1.59+/-0.51; 1.52+/-0.4 mg/dL; P<.001), received lower CsA doses (172+/-54; 207+/-54; 227+/-56 mg/d, P<.01), showed lower C0 levels (155+/-48; 172+/-41; 199+/-45 ng/mL; P< .001), and included more patients on triple therapy (54.5%; 44%; 17.2%; P<.05). We found weak correlations between C0 and C2 (r=0.37), between C2 and CsA dose (r=0.36), and between C0 and SCr (r=-0.37). Among 117 patients followed up for 1 year with several C0 and C2 measurements, the coefficient of variation of C0 was 17% and of C2 was 21%. Graft functional deterioration occurred in 16 patients independent of the differences among the C2 groups, but 7 recipients (43.7%) had C0 <150 ng/mL and C2/C0 >5. We conclude that C2 in monitoring stable patients needs further evaluation.
近期数据显示,对初发肾移植患者,监测环孢素A(CsA)给药后2小时血药浓度(C2)与排斥反应发生率及移植肾预后相关。本研究旨在评估肾移植术后1年进行C2监测的优势。我们研究了161例患者,其中96例接受CsA - 泼尼松治疗,65例接受三联疗法(硫唑嘌呤或霉酚酸酯),平均移植时间为103±44个月。平均血清肌酐(SCr)为1.65±0.69mg/dL,平均C0为174±44,C2为667±194ng/mL。根据C2值将患者分类:>850(n = 29)、850至450之间(n = 109)和<450(n = 23)ng/mL。C2<450ng/mL的患者SCr值更高(1.97±0.99;1.59±0.51;1.52±0.4mg/dL;P<0.001),CsA剂量更低(172±54;207±54;227±56mg/d,P<0.01),C0水平更低(155±48;172±41;199±45ng/mL;P<0.001),且三联疗法的患者更多(54.5%;44%;17.2%;P<0.05)。我们发现C0与C2之间(r = 0.37)、C2与CsA剂量之间(r = 0.36)以及C0与SCr之间(r = -0.37)存在弱相关性。在117例接受多次C0和C2测量并随访1年的患者中,C0的变异系数为17%,C2的变异系数为21%。16例患者出现移植肾功能恶化,与C2组间差异无关,但7例受者(43.7%)C0<150ng/mL且C2/C0>5。我们得出结论,C2在监测稳定患者方面需要进一步评估。